GH Research PLC is a clinical-stage biopharmaceutical company headquartered in Dublin, Ireland, focused on developing treatments for depression and related psychiatric conditions. The company's lead program, GH001, is an inhalable formulation of mebufotenin currently in phase 2b testing for treatment-resistant depression, with additional phase 2a trials underway in bipolar II disorder with concurrent major depressive episodes and postpartum depression in female patients. A secondary candidate, GH002, is an intravenous mebufotenin formulation in early-stage phase 1 clinical pharmacology testing in healthy volunteers for potential psychiatric and neurological applications.
The company operates as a development-stage entity with no approved products or commercial revenue streams. GH Research maintains a lean operational structure with approximately 50 full-time employees and is incorporated in Ireland, where it maintains its primary operations. The company is traded on Nasdaq, with a market capitalization of $0.9 billion as of the available reporting date. Founded in 2018, GH Research targets the U.S. market for its psychiatric treatment programs, with clinical development representing its primary business activity during this phase of development.
No 10-K filings found.